142 related articles for article (PubMed ID: 27038302)
1. Comparing biomarkers as trial level general surrogates.
Gabriel EE; Daniels MJ; Halloran ME
Biometrics; 2016 Dec; 72(4):1046-1054. PubMed ID: 27038302
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and comparison of predictive individual-level general surrogates.
Gabriel EE; Sachs MC; Halloran ME
Biostatistics; 2018 Jul; 19(3):307-324. PubMed ID: 28968890
[TBL] [Abstract][Full Text] [Related]
3. Optimizing and evaluating biomarker combinations as trial-level general surrogates.
Gabriel EE; Sachs MC; Daniels MJ; Halloran ME
Stat Med; 2019 Mar; 38(7):1135-1146. PubMed ID: 30306600
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.
Zigler CM; Belin TR
Biometrics; 2012 Sep; 68(3):922-32. PubMed ID: 22348277
[TBL] [Abstract][Full Text] [Related]
6. Flexible evaluation of surrogacy in platform studies.
Sachs MC; Gabriel EE; Crippa A; Daniels MJ
Biostatistics; 2023 Dec; 25(1):220-236. PubMed ID: 36610075
[TBL] [Abstract][Full Text] [Related]
7. Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints.
Gabriel EE; Sachs MC; Gilbert PB
Stat Med; 2015 Feb; 34(3):381-95. PubMed ID: 25352131
[TBL] [Abstract][Full Text] [Related]
8. Evaluating surrogate markers of clinical outcome when measured with error.
Dafni UG; Tsiatis AA
Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
[TBL] [Abstract][Full Text] [Related]
9. Bayesian adaptive trial design for a newly validated surrogate endpoint.
Renfro LA; Carlin BP; Sargent DJ
Biometrics; 2012 Mar; 68(1):258-67. PubMed ID: 21838811
[TBL] [Abstract][Full Text] [Related]
10. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
11. An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error.
Belhechmi S; Michiels S; Paoletti X; Rotolo F
Contemp Clin Trials Commun; 2019 Sep; 15():100402. PubMed ID: 31338479
[TBL] [Abstract][Full Text] [Related]
12. Surrogate measures and consistent surrogates.
Vanderweele TJ
Biometrics; 2013 Sep; 69(3):561-9. PubMed ID: 24073861
[TBL] [Abstract][Full Text] [Related]
13. Evaluating candidate principal surrogate endpoints.
Gilbert PB; Hudgens MG
Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
[TBL] [Abstract][Full Text] [Related]
14. Comparing biomarkers as principal surrogate endpoints.
Huang Y; Gilbert PB
Biometrics; 2011 Dec; 67(4):1442-51. PubMed ID: 21517791
[TBL] [Abstract][Full Text] [Related]
15. Evaluating a surrogate endpoint at three levels, with application to vaccine development.
Gilbert PB; Qin L; Self SG
Stat Med; 2008 Oct; 27(23):4758-78. PubMed ID: 17979212
[TBL] [Abstract][Full Text] [Related]
16. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
Black S
Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
[TBL] [Abstract][Full Text] [Related]
17. Design and estimation for evaluating principal surrogate markers in vaccine trials.
Huang Y; Gilbert PB; Wolfson J
Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
[TBL] [Abstract][Full Text] [Related]
18. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
19. Augmented trial designs for evaluation of principal surrogates.
Gabriel EE; Follmann D
Biostatistics; 2016 Jul; 17(3):453-67. PubMed ID: 26825099
[TBL] [Abstract][Full Text] [Related]
20. Predictive cluster level surrogacy in the presence of interference.
Gabriel EE; Follmann DA
Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
